Targeted protein degradation is being explored instead method in cancer, whereby the organic protein degradation process is co-opted for therapeutic reasons. Recently designed novel molecules termed proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules with two ligands joined by a linker. Just one ligand binds on the ‘protein of interest’ (POI) and https://www.directivepublications.org/journal-of-clinical-breast-cancer/